Fri, November 19, 2021

Do Kim Downgraded (VRTX) to Hold and Decreased Target to $218 on, Nov 19th, 2021

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. nd-decreased-target-to-218-on-nov-19th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Do Kim of Piper Sandler, Downgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold and Decreased Target from $323 to $218 on, Nov 19th, 2021.

Do has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 1 agrees with Do's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021


These are the ratings of the 6 analyists that currently disagree with Do


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $250 on, Wednesday, November 3rd, 2021
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Tuesday, November 2nd, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Tuesday, October 19th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $323 on, Friday, July 30th, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Sell with Increased Target to $175 on, Friday, July 30th, 2021